Deals Of The Week: Stiefel/Welichem, Bayer/Covance, Ensemble/Genentech

Activist investor Carl Icahn is at it again, announcing plans May 30 to propose a minority slate of new board members for patent-cliff-challenged specialty pharma Forest Laboratories.